Literature DB >> 18289858

Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein.

Ferenc Zsila1, Júlia Visy, György Mády, Ilona Fitos.   

Abstract

Human plasma protein binding of six antimalarial agents of quinoline and acridine types was investigated by using spectroscopic techniques, affinity chromatography, ultrafiltration and HPLC methods. Induced circular dichroism (ICD) spectra showed binding of amodiaquine (AMQ), primaquine (PRQ), tafenoquine (TFQ), and quinacrine (QR) to alpha(1)-acid glycoprotein (AAG), the serum level of which greatly increases in Plasmodium infections. Association constant (K(a)) values of about 10(5)-10(6) M(-1) could be determined. Analysis of the ICD and UV spectra of the drug-AAG complexes suggested the inclusion of the ligands into the central hydrophobic cavity of the protein. Using the purified forms of the two main genetic variants of AAG, ICD data indicated the selective binding of AMQ and PRQ to the 'F1/S', while QR to the 'A' variant. Results of fluorescence experiments supported the AAG binding of these drugs and provided further insights into the binding details of TFQ and QR. Fluorescence and CD displacement experiments showed the high-affinity AAG binding of mefloquine (K(a) approximately 10(6) M(-1)). For this drug, inverse binding stereoselectivities were found with the 'F1/S' and 'A' genetic variants of AAG. HSA association constants estimated from affinity chromatography results lag behind (10(3)-10(5) M(-1)) the similar values derived for AAG. In case of chloroquine, no significant binding interaction was found either with AAG or HSA. Pharmacological aspects of the results are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18289858     DOI: 10.1016/j.bmc.2008.01.053

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  Calculation of normalized drug concentrations in the presence of altered plasma protein binding.

Authors:  Florin Marcel Musteata
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children.

Authors:  Trevor N Johnson; Yumi Cleary; Neil Parrott; Bruno Reigner; James R Smith; Stephen Toovey
Journal:  Br J Clin Pharmacol       Date:  2018-11-05       Impact factor: 4.335

3.  Association of Lipid Levels with Mefloquine and Carboxy-Mefloquine Concentrations in Patients with Uncomplicated Falciparum Malaria.

Authors:  José Luiz Fernandes Vieira; Juan Gonzalo Bardalez Rivera; Luann Wendel Pereira de Sena; Michelle Valeria Dias Ferreira
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 4.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.

Authors:  Parag Aggarwal; Jennifer B Hall; Christopher B McLeland; Marina A Dobrovolskaia; Scott E McNeil
Journal:  Adv Drug Deliv Rev       Date:  2009-04-17       Impact factor: 15.470

Review 5.  Stereoselective binding of chiral drugs to plasma proteins.

Authors:  Qi Shen; Lu Wang; Hui Zhou; Hui-di Jiang; Lu-shan Yu; Su Zeng
Journal:  Acta Pharmacol Sin       Date:  2013-07-15       Impact factor: 6.150

6.  Pharmacokinetic interactions between primaquine and chloroquine.

Authors:  Sasithon Pukrittayakamee; Joel Tarning; Podjanee Jittamala; Prakaykaew Charunwatthana; Saranath Lawpoolsri; Sue J Lee; Warunee Hanpithakpong; Borimas Hanboonkunupakarn; Nicholas P J Day; Elizabeth A Ashley; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

7.  Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing.

Authors:  Ali Mohamed Ali; Melissa A Penny; Thomas A Smith; Lesley Workman; Philip Sasi; George O Adjei; Francesca Aweeka; Jean-René Kiechel; Vincent Jullien; Marcus J Rijken; Rose McGready; Julia Mwesigwa; Kim Kristensen; Kasia Stepniewska; Joel Tarning; Karen I Barnes; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.